SCC-9 Cells - Head-Neck cancer cell lines
Produktgrößen
1 each
£607,00
305390-1EACH
Über dieses Produkt
- SKU:
- 305390
- Zusätzliche Namen:
- SCC 9, SCC9, SFCI-SCC-09
- CE/IVD:
- Our cells are provided for in vitro laboratory research purposes exclusively and are not intended fo
- Weitere Details:
- SCC-9 is a human oral squamous cell carcinoma (OSCC) cell line commonly used in research focused on head and neck cancers, particularly in studying tumor progression, apoptosis, and treatment efficacy. OSCC is a prevalent form of head and neck cancer with a low 5-year survival rate, making cell lines like SCC-9 essential for understanding cancer biology and exploring potential therapeutic strategies. SCC-9 cells have been utilized in studies to assess the effects of various chemotherapeutic agents and natural compounds on oral cancer. For example, quercetin, a dietary flavonoid, has been shown to induce both necrosis and apoptosis in SCC-9 cells in a time- and dose-dependent manner. Quercetin's antiproliferative effects were linked to the inhibition of thymidylate synthase, a key enzyme in DNA synthesis, leading to S-phase arrest in the cell cycle. The induction of necrosis was observed early, while prolonged exposure led to apoptosis through caspase-3 activation. Similarly, curcumin has been demonstrated to inhibit SCC-9 cell proliferation by regulating miR-9 expression, a microRNA associated with tumor suppression. Curcumin suppresses the Wnt/B Beta-catenin signaling pathway, thereby reducing the levels of key oncogenic factors like cyclin D1. These findings highlight the relevance of SCC-9 cells in testing novel anticancer agents and unraveling the molecular mechanisms of OSCC development, particularly in targeting pathways like Wnt/B Beta-catenin and assessing the role of apoptosis and cell cycle regulation.
- Versandbedingungen:
- Dry Ice
- Lagerbedingungen:
- Liquid N2, -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Cytion
- Typ:
- Cells: Cell Lines
- Datenblatt des Herstellers:0192b91ef512743ea82e55fa0ef50bad